Dexfenfluramine: no increase in significant valvular abnormalities

    loading  Checking for direct PDF access through Ovid


There appears to be no increase in the prevalence of clinically relevant mitral or aortic regurgitation following 2-3 months' therapy with the anorectic agent dexfenfluramine [‘Redux’], compared with placebo, according to the results of a study presented at the 47th Annual Scientific Sessions of the American College of Cardiology (ACC) [Atlanta, US; March 1998]. In addition, the prevalence of significant valvular regurgitation following treatment with dexfenfluramine appears to be much lower than previously reported.

Related Topics

    loading  Loading Related Articles